{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:14:06Z","timestamp":1740172446568,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006470","name":"Aristotle University of Thessaloniki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006470","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Non-invasive diagnosis of nonalcoholic fatty liver disease (NAFLD) and its advanced phenotypes (e.g., nonalcoholic steatohepatitis; NASH) is a hot research topic. The aim of this report was the validation of a novel non-invasive index of NAFLD, the \u201cNAFLD test,\u201d recently introduced for the diagnosis of NAFLD (vs. non-NAFLD controls).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a post-hoc analysis of a previous study. The NAFLD test was calculated in NAFLD patients and non-NAFLD controls; the performance of the test was compared with that of other non-invasive indices of NAFLD (fatty liver index [FLI] and hepatic steatosis index [HSI]), and other indices of NASH (index of NASH [ION] and cytokeratin-18\/homeostasis model assessment-insulin resistance\/aspartate transaminase index [CHAI]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The NAFLD test was higher in NAFLD patients than in controls (1.89\u2009\u00b1\u20090.14 vs. 1.30\u2009\u00b1\u20090.06, respectively; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). In NAFLD patients, the NAFLD test was higher in NASH patients than in those with simple nonalcoholic fatty liver (NAFL) (2.21\u2009\u00b1\u20090.24 vs. 1.57\u2009\u00b1\u20090.08, respectively; <jats:italic>p<\/jats:italic>\u2009=\u20090.007). The area under the receiver operating characteristic curve (AUC) of the NAFLD test was 0.84 (95% CI: 0.74\u20130.94; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) for differentiation between NAFLD and non-NAFLD controls and its performance was similar to that for FLI and HSI. For differentiation between NASH and NAFL patients, the AUC of the NAFLD test was 0.88 (95% CI: 0.62\u20130.96; <jats:italic>p<\/jats:italic>\u2009=\u20090.007) and its performance was superior to that for ION and CHAI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The NAFLD test was validated in this external cohort for the non-invasive diagnosis of NAFLD patients vs. non-NAFLD individuals. It was also shown to differentiate between NASH and NAFL patients with acceptable accuracy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s42000-023-00502-1","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T01:01:57Z","timestamp":1699837317000},"page":"131-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nonalcoholic fatty liver disease test: an external validation cohort"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-4042","authenticated-orcid":false,"given":"Stergios A.","family":"Polyzos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolis","family":"Papaefthymiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Doulberis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jannis","family":"Kountouras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"key":"502_CR1","doi-asserted-by":"publisher","first-page":"154203","DOI":"10.1016\/j.metabol.2020.154203","volume":"111S","author":"SA Polyzos","year":"2020","unstructured":"Polyzos SA, Kang ES, Boutari C, Rhee EJ, Mantzoros CS (2020) Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 111S:154203","journal-title":"Metabolism"},{"issue":"4","key":"502_CR2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Minhui Paik J, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F (2019) The Global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 71(4):793\u2013801","journal-title":"J Hepatol"},{"key":"502_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne C, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer D, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot B, Korenjak M, Kowdley K, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell E, Roden M, Romero-G\u00f3mez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wai-Sun Wong V, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN (2023) A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003","journal-title":"J Hepatol"},{"issue":"1","key":"502_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.arcmed.2020.11.010","volume":"52","author":"E Makri","year":"2021","unstructured":"Makri E, Goulas A, Polyzos SA (2021) Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res 52(1):25\u201337","journal-title":"Arch Med Res"},{"key":"502_CR5","doi-asserted-by":"publisher","first-page":"155666","DOI":"10.1016\/j.metabol.2023.155666","volume":"147","author":"M Kouvari","year":"2023","unstructured":"Kouvari M, Valenzuela-Vallejo L, Guatibonza-Garcia V, Polyzos SA, Deng Y, Kokkorakis M, Agraz M, Mylonakis SC, Katsarou A, Verrastro O, Markakis G, Eslam M, Papatheodoridis G, George J, Mingrone G, Mantzoros CS (2023) Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study. Metabolism 147:155666","journal-title":"Metabolism"},{"key":"502_CR6","doi-asserted-by":"publisher","first-page":"154005","DOI":"10.1016\/j.metabol.2019.154005","volume":"101","author":"N Perakakis","year":"2019","unstructured":"Perakakis N, Polyzos SA, Yazdani A, Sala-Vila A, Kountouras J, Anastasilakis AD, Mantzoros CS (2019) Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. Metabolism 101:154005","journal-title":"Metabolism"},{"issue":"3","key":"502_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s42000-022-00377-8","volume":"21","author":"S Kechagias","year":"2022","unstructured":"Kechagias S, Ekstedt M, Simonsson C, Nasr P (2022) Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. Hormones (Athens) 21(3):349\u2013368","journal-title":"Hormones (Athens)"},{"issue":"2","key":"502_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.metabol.2013.10.010","volume":"63","author":"SA Polyzos","year":"2014","unstructured":"Polyzos SA, Mantzoros CS (2014) Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 63(2):161\u2013167","journal-title":"Metabolism"},{"issue":"2","key":"502_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2174\/1570161117666190405164313","volume":"18","author":"VG Athyros","year":"2020","unstructured":"Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS (2020) Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block. Curr Vasc Pharmacol 18(2):172\u2013181","journal-title":"Curr Vasc Pharmacol"},{"issue":"8","key":"502_CR10","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/MEG.0000000000002575","volume":"35","author":"M Omran","year":"2023","unstructured":"Omran M, Omr M, Mohamed AA, Abdelghafour RA, Muharram NM, Hassan MB, Fangry A, Emran T, Arab JP, Arnold J, Diaz LA, Zheng MH, El-Kassas M (2023) Development and validation of nonalcoholic fatty liver disease test: a simple sensitive and specific marker for early diagnosis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 35(8):874\u2013880","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"502_CR11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1665-2681(19)31316-X","volume":"12","author":"SA Polyzos","year":"2013","unstructured":"Polyzos SA, Kountouras J, Papatheodorou A, Katsiki E, Patsiaoura K, Zafeiriadou E, Papadopoulou E, Zavos C, Terpos E (2013) Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: introduction of CHA index. Ann Hepatol 12(5):749\u2013757","journal-title":"Ann Hepatol"},{"key":"502_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C (2006) The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:33","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"502_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, Lee HS (2010) Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 42(7):503\u2013508","journal-title":"Dig Liver Dis"},{"issue":"12","key":"502_CR14","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1111\/jgh.12665","volume":"29","author":"M Otgonsuren","year":"2014","unstructured":"Otgonsuren M, Estep MJ, Hossain N, Younossi E, Frost S, Henry L, Hunt S, Fang Y, Goodman Z, Younossi ZM (2014) Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). J Gastroenterol Hepatol 29(12):2006\u20132013","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-023-00502-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-023-00502-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-023-00502-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T04:51:13Z","timestamp":1707281473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-023-00502-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1007\/s42000-023-00502-1","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"type":"print","value":"1109-3099"},{"type":"electronic","value":"2520-8721"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"assertion":[{"value":"8 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Medical School, Aristotle University of Thessaloniki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All participants provided signed informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}